Back to Search Start Over

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.

Authors :
Neri P
Leblay N
Lee H
Gulla A
Bahlis NJ
Anderson KC
Source :
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2024 Aug; Vol. 21 (8), pp. 590-609. Date of Electronic Publication: 2024 Jul 03.
Publication Year :
2024

Abstract

A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including multiple myeloma (MM) has led to the development of novel immune-based therapies. B cell maturation antigen (BCMA), G protein-coupled receptor family C group 5 member D (GPRC5D) and Fc receptor-like protein 5 (FcRL5, also known as FcRH5) are cell-surface transmembrane proteins expressed by plasma cells, and have been identified as prominent immunotherapeutic targets in MM, with promising activity demonstrated in patients with heavily pretreated relapsed and/or refractory disease. Indeed, since 2020, antibody-drug conjugates, bispecific T cell engagers and autologous chimeric antigen receptor T cells targeting BCMA or GPRC5D have been approved for the treatment of relapsed and/or refractory MM. However, responses to these therapies are not universal, and acquired resistance invariably occurs. In this Review, we discuss the various immunotherapeutic approaches targeting BCMA, GPRC5D and FcRL5 that are currently either available or in clinical development for patients with MM. We also review the mechanisms underlying resistance to such therapies, and discuss potential strategies to overcome these mechanisms and improve patient outcomes.<br /> (© 2024. Springer Nature Limited.)

Details

Language :
English
ISSN :
1759-4782
Volume :
21
Issue :
8
Database :
MEDLINE
Journal :
Nature reviews. Clinical oncology
Publication Type :
Academic Journal
Accession number :
38961233
Full Text :
https://doi.org/10.1038/s41571-024-00913-y